Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

NCT00103844 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia
Philadelphia-Positive Myeloid Leukemia

Interventions

DRUG: Dasatinib
DRUG: Imatinib

Sponsor

Bristol-Myers Squibb